| 42.21 Delayed Data As of Jan 16 |  -0.03 / -0.07%Today’s Change | 37.43 Today|||52-Week Range 45.86 | -2.76% Year-to-Date |
| Regeneron (REGN) Sails Steady on Label Expansion of Drugs Jan 16 / Zacks.com - Paid Partner Content | Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results Jan 08 / Zacks.com - Paid Partner Content |
| 6 Stocks With Low Price-Sales Ratios Jan 11 / GuruFocus News - Paid Partner Content | Regeneron, Sanofi Restructure Immuno-Oncology Collaboration Jan 07 / Zacks.com - Paid Partner Content |
| Previous close | 42.24 |
| Today’s open | 42.25 |
| Day’s range | 42.19 - 42.45 |
| Volume | 519,772 |
| Average volume (3 months) | 1,211,917 |
| Market cap | $112.3B |
| Earnings growth (last year) | -15.68% |
| Earnings growth (this year) | -6.41% |
| Earnings growth (next 5 years) | +5.95% |
| Revenue growth (last year) | +5.92% |
| P/E ratio | 28.6 |
| Price/Sales | 2.76 |
| Price/Book | 1.61 |
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | -0.29 | -0.25% |
| AZNAstraZeneca | -0.32 | -0.89% |
| ABTAbbott Laboratories | -0.65 | -0.92% |
| GSKGlaxoSmithKline | -0.64 | -1.64% |
| Next reporting date | February 7, 2019 |
| EPS forecast (this quarter) | $0.62 |
| Annual revenue (last year) | $39.5B |
| Annual profit (last year) | $4.3B |
| Net profit margin | 10.81% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Olivier Brandicourt |
Chief Financial Officer & Executive Vice President Jean-Baptiste Chasseloup de Chatillon |
Corporate headquarters Paris, Ile-de-france |
